Anika Therapeutics Stock
Price
Target price
€7.95
€7.95
0.630%
0.05
0.630%
€15.41
07.01.26 / Frankfurt
WKN: 889120 / Symbol: ANIK / Name: Anika / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Anika Therapeutics Stock
Anika Therapeutics gained 0.630% compared to yesterday.
Anika Therapeutics is currently one of the favorites of our community with 9 Buy predictions and no Sell predictions.
With a target price of 15 € there is a hugely positive potential of 88.68% for Anika Therapeutics compared to the current price of 7.95 €.
Our community identified positive and negative aspects for Anika Therapeutics stock for the coming years. 1 users see the criterium "Brand" as a plus for the Anika Therapeutics stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Anika Therapeutics in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Cons
?
B****
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Anika Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Anika Therapeutics | 0.630% | -0.625% | -3.049% | -47.351% | -0.625% | -72.007% | -78.856% |
| Ardelyx Inc. | 20.070% | 22.231% | 18.703% | 16.087% | 22.231% | 122.288% | 11.765% |
| Evolus Inc | 0.000% | -13.394% | -17.193% | -52.800% | -13.394% | -35.782% | 53.947% |
| Champions Oncology Inc | -0.910% | -6.034% | 9.000% | 14.496% | -6.034% | 36.250% | -39.444% |
Comments
Anika Therapeutics (NASDAQ:ANIK) had its price target raised by analysts at Barrington Research from $15.00 to $16.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ANIK provided by MarketBeat
Anika Therapeutics (NASDAQ:ANIK) had its "outperform" rating reaffirmed by analysts at Barrington Research. They now have a $15.00 price target on the stock.
Show more
Ratings data for ANIK provided by MarketBeat
Anika Therapeutics Inc. (NASDAQ: ANIK) had its price target lowered by analysts at Barrington Research from $19.00 to $15.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ANIK provided by MarketBeat
News
Anika (ANIK) Q2 Revenue Beats by 4%
Anika Therapeutics (NASDAQ:ANIK), a medical technology company focused on joint preservation and regenerative therapy products, released its earnings on July 30, 2025. The key news from the release
